Discontinued — last reported Q2 '21
Other
Remaining commitment for R&D funding agreement
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ1 2021
Last reportedQ2 2021Aug 11, 2021
Metric ID:
other_research_and_development_remaining_funding_commitmentHistorical Data
1 periods
| Q2 '21 | |
|---|---|
| Value | $11.4M |
Frequently Asked Questions
- What is Royalty Pharma's remaining commitment for r&d funding agreement?
- Royalty Pharma (RPRX) reported remaining commitment for r&d funding agreement of $11.4M in Q2 2021.